{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T11:37:27Z","timestamp":1775821047170,"version":"3.50.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T00:00:00Z","timestamp":1747008000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"CSL Vifor"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s41669-025-00581-3","type":"journal-article","created":{"date-parts":[[2025,5,12]],"date-time":"2025-05-12T02:07:30Z","timestamp":1747015650000},"page":"693-706","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Economic Evaluation of Patiromer in Patients with Concomitant Heart Failure and Chronic Kidney Disease in Italy"],"prefix":"10.1007","volume":"9","author":[{"given":"M.","family":"Senni","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Paoletti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Stawowczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. Ramirez","family":"de Arellano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,5,12]]},"reference":[{"issue":"2","key":"581_CR1","doi-asserted-by":"publisher","first-page":"238","DOI":"10.3390\/ijerph13020238","volume":"13","author":"A Buja","year":"2016","unstructured":"Buja A, Solinas G, Visca M, Federico B, Gini R, Baldo V, et al. Prevalence of heart failure and adherence to process indicators: which socio-demographic determinants are involved? Int J Environ Res Public Health. 2016;13(2):238.","journal-title":"Int J Environ Res Public Health"},{"issue":"4","key":"581_CR2","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1002\/ejhf.471","volume":"18","author":"AP Maggioni","year":"2016","unstructured":"Maggioni AP, Orso F, Calabria S, Rossi E, Cinconze E, Baldasseroni S, et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail. 2016;18(4):402\u201310.","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"581_CR3","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1007\/s40292-017-0193-4","volume":"24","author":"C Piccinni","year":"2017","unstructured":"Piccinni C, Antonazzo IC, Simonetti M, Mennuni MG, Parretti D, Cricelli C, et al. The burden of chronic heart failure in primary care in Italy. High Blood Press Cardiovasc Prev. 2017;24(2):171\u20138.","journal-title":"High Blood Press Cardiovasc Prev."},{"issue":"5","key":"581_CR4","doi-asserted-by":"publisher","first-page":"272","DOI":"10.1177\/0885066605278969","volume":"20","author":"KJ Evans","year":"2005","unstructured":"Evans KJ, Greenberg A. Hyperkalemia: a review. J Intensive Care Med. 2005;20(5):272\u201390.","journal-title":"J Intensive Care Med"},{"issue":"12","key":"581_CR5","doi-asserted-by":"publisher","first-page":"934","DOI":"10.3949\/ccjm.84a.17056","volume":"84","author":"BF Palmer","year":"2017","unstructured":"Palmer BF, Clegg DJ. Diagnosis and treatment of hyperkalemia. Cleve Clin J Med. 2017;84(12):934\u201342.","journal-title":"Cleve Clin J Med"},{"issue":"3","key":"581_CR6","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1093\/ehjcvp\/pvy015","volume":"4","author":"GMC Rosano","year":"2018","unstructured":"Rosano GMC, Tamargo J, Kjeldsen KP, Lainscak M, Agewall S, Anker SD, et al. Expert consensus document on the management of hyperkalaemia in patients with cardiovascular disease treated with renin angiotensin aldosterone system inhibitors: coordinated by the Working Group on Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2018;4(3):180\u20138.","journal-title":"Eur Heart J Cardiovasc Pharmacother."},{"key":"581_CR7","unstructured":"National Institute for Health and Care Excellence: Guidelines. Chronic heart failure in adults: diagnosis and management. London: National Institute for Health and Care Excellence (NICE) Copyright \u00a9 NICE 2018; 2018."},{"issue":"11 Suppl","key":"581_CR8","first-page":"S212","volume":"21","author":"M Epstein","year":"2015","unstructured":"Epstein M, Reaven NL, Funk SE, McGaughey KJ, Oestreicher N, Knispel J. Evaluation of the treatment gap between clinical guidelines and the utilization of renin-angiotensin-aldosterone system inhibitors. Am J Manag Care. 2015;21(11 Suppl):S212\u201320.","journal-title":"Am J Manag Care"},{"key":"581_CR9","unstructured":"Network HFP. Heart failure policy and practice in Europe: Italy. London; 2020."},{"key":"581_CR10","doi-asserted-by":"crossref","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891\u2013975.","DOI":"10.1002\/ejhf.592"},{"issue":"8","key":"581_CR11","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1002\/ejhf.1199","volume":"20","author":"M Trevisan","year":"2018","unstructured":"Trevisan M, de Deco P, Xu H, Evans M, Lindholm B, Bellocco R, et al. Incidence, predictors and clinical management of hyperkalaemia in new users of mineralocorticoid receptor antagonists. Eur J Heart Fail. 2018;20(8):1217\u201326.","journal-title":"Eur J Heart Fail"},{"issue":"10","key":"581_CR12","doi-asserted-by":"publisher","first-page":"1698","DOI":"10.1002\/ejhf.2287","volume":"23","author":"M Trevisan","year":"2021","unstructured":"Trevisan M, Fu EL, Xu Y, Savarese G, Dekker FW, Lund LH, et al. Stopping mineralocorticoid receptor antagonists after hyperkalaemia: trial emulation in data from routine care. Eur J Heart Fail. 2021;23(10):1698\u2013707.","journal-title":"Eur J Heart Fail"},{"key":"581_CR13","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ahj.2021.09.014","volume":"243","author":"Y Xu","year":"2022","unstructured":"Xu Y, Fu EL, Trevisan M, Jernberg T, Sj\u00f6lander A, Clase CM, et al. Stopping renin-angiotensin system inhibitors after hyperkalemia and risk of adverse outcomes. Am Heart J. 2022;243:177\u201386.","journal-title":"Am Heart J"},{"issue":"2","key":"581_CR14","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1002\/ehf2.12402","volume":"6","author":"C Linde","year":"2019","unstructured":"Linde C, Qin L, Bakhai A, Furuland H, Evans M, Ayoubkhani D, et al. Serum potassium and clinical outcomes in heart failure patients: results of risk calculations in 21 334 patients in the UK. ESC Heart Fail. 2019;6(2):280\u201390.","journal-title":"ESC Heart Fail."},{"issue":"5","key":"581_CR15","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.13475","volume":"74","author":"M Provenzano","year":"2020","unstructured":"Provenzano M, De Francesco M, Iannazzo S, Garofalo C, Andreucci M, Genualdo R, et al. Cost-analysis of persistent hyperkalaemia in non-dialysis chronic kidney disease patients under nephrology care in Italy. Int J Clin Pract. 2020;74(5): e13475.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"581_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13551","volume":"51","author":"AP Maggioni","year":"2021","unstructured":"Maggioni AP, Dondi L, Andreotti F, Calabria S, Iacoviello M, Gorini M, et al. Prevalence, clinical impact and costs of hyperkalaemia: Special focus on heart failure. Eur J Clin Invest. 2021;51(8): e13551.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"581_CR17","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1186\/s12882-020-01942-2","volume":"21","author":"JS Haas","year":"2020","unstructured":"Haas JS, Krinke KS, Maas C, Hardt T, Barck I, Braun S. The burden of hyperkalemia in Germany\u2014a real world evidence study assessing the treatment and costs of hyperkalemia. BMC Nephrol. 2020;21(1):332.","journal-title":"BMC Nephrol"},{"issue":"4","key":"581_CR18","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.recesp.2020.06.016","volume":"74","author":"S Jim\u00e9nez-Marrero","year":"2021","unstructured":"Jim\u00e9nez-Marrero S, Cainzos-Achirica M, Monterde D, Vela E, Cleries M, Garc\u00eda-Eroles L, et al. Impact on clinical outcomes and health costs of deranged potassium levels in patients with chronic cardiovascular, metabolic, and renal conditions. Rev Esp Cardiol (Engl Ed). 2021;74(4):312\u201320.","journal-title":"Rev Esp Cardiol (Engl Ed)."},{"issue":"4","key":"581_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2018-026465","volume":"9","author":"K Kim","year":"2019","unstructured":"Kim K, Thomsen RW, Nicolaisen SK, Hasvold LP, Palaka E, S\u00f8rensen HT. Healthcare resource utilisation and cost associated with elevated potassium levels: a Danish population-based cohort study. BMJ Open. 2019;9(4): e026465.","journal-title":"BMJ Open"},{"key":"581_CR20","doi-asserted-by":"crossref","unstructured":"Olry de Labry Lima A, D\u00edaz Castro \u00d3, Romero-Requena JM, Garc\u00eda D\u00edaz-Guerra MLR, Arroyo Pineda V, de la Hija D\u00edaz MB, et al. Hyperkalaemia management and related costs in chronic kidney disease patients with comorbidities in Spain. Clin Kidney J. 2021;14(11):2391\u2013400.","DOI":"10.1093\/ckj\/sfab076"},{"issue":"4","key":"581_CR21","doi-asserted-by":"publisher","first-page":"296","DOI":"10.4212\/cjhp.v68i4.1469","volume":"68","author":"J Batterink","year":"2015","unstructured":"Batterink J, Lin J, Au-Yeung SH, Cessford T. Effectiveness of sodium polystyrene sulfonate for short-term treatment of hyperkalemia. Can J Hosp Pharm. 2015;68(4):296\u2013303.","journal-title":"Can J Hosp Pharm"},{"issue":"1","key":"581_CR22","first-page":"43","volume":"41","author":"M Chaitman","year":"2016","unstructured":"Chaitman M, Dixit D, Bridgeman MB. Potassium-binding agents for the clinical management of hyperkalemia. P t. 2016;41(1):43\u201350.","journal-title":"P t"},{"issue":"1","key":"581_CR23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/ehf2.12221","volume":"5","author":"T Okabe","year":"2018","unstructured":"Okabe T, Yakushiji T, Kido T, Oyama Y, Igawa W, Ono M, et al. The association between high-dose loop diuretic use at discharge and cardiovascular mortality in patients with heart failure. ESC Heart Fail. 2018;5(1):87\u201394.","journal-title":"ESC Heart Fail."},{"issue":"41","key":"581_CR24","doi-asserted-by":"publisher","first-page":"4362","DOI":"10.1093\/eurheartj\/ehac401","volume":"43","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Lund LH, Coats AJS, Filippatos G, Siddiqi TJ, et al. Patiromer for the management of hyperkalemia in heart failure with reduced ejection fraction: the DIAMOND trial. Eur Heart J. 2022;43(41):4362\u201373.","journal-title":"Eur Heart J"},{"issue":"7","key":"581_CR25","doi-asserted-by":"publisher","first-page":"820","DOI":"10.1093\/eurheartj\/ehq502","volume":"32","author":"B Pitt","year":"2011","unstructured":"Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ. Evaluation of the efficacy and safety of RLY5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the PEARL-HF) trial. Eur Heart J. 2011;32(7):820\u20138.","journal-title":"Eur Heart J"},{"issue":"10","key":"581_CR26","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1002\/ejhf.402","volume":"17","author":"B Pitt","year":"2015","unstructured":"Pitt B, Bakris GL, Bushinsky DA, Garza D, Mayo MR, Stasiv Y, et al. Effect of patiromer on reducing serum potassium and preventing recurrent hyperkalaemia in patients with heart failure and chronic kidney disease on RAAS inhibitors. Eur J Heart Fail. 2015;17(10):1057\u201365.","journal-title":"Eur J Heart Fail"},{"issue":"5","key":"581_CR27","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s41669-022-00357-z","volume":"6","author":"T Ward","year":"2022","unstructured":"Ward T, Brown T, Lewis RD, Kliess MK, de Arellano AR, Quinn CM. The cost effectiveness of patiromer for the treatment of hyperkalaemia in patients with chronic kidney disease with and without heart failure in Ireland. Pharmacoecon Open. 2022;6(5):757\u201371.","journal-title":"Pharmacoecon Open."},{"issue":"1","key":"581_CR28","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/s12882-023-03088-3","volume":"24","author":"T Ward","year":"2023","unstructured":"Ward T, Lewis RD, Brown T, Baxter G, de Arellano AR. A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure. BMC Nephrol. 2023;24(1):47.","journal-title":"BMC Nephrol"},{"issue":"7","key":"581_CR29","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s40273-020-00902-w","volume":"38","author":"J Wid\u00e9n","year":"2020","unstructured":"Wid\u00e9n J, Ivarsson M, Schalin L, Vrouchou P, Schwenkglenks M, Heimb\u00fcrger O, et al. Cost-effectiveness analysis of patiromer in combination with renin-angiotensin-aldosterone system inhibitors for chronic kidney disease in Sweden. Pharmacoeconomics. 2020;38(7):747\u201364.","journal-title":"Pharmacoeconomics"},{"key":"581_CR30","unstructured":"Members: ATF, McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2022;24(1):4\u2013131."},{"issue":"1","key":"581_CR31","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1002\/ejhf.2386","volume":"24","author":"J Butler","year":"2022","unstructured":"Butler J, Anker SD, Siddiqi TJ, Coats AJS, Dorigotti F, Filippatos G, et al. Patiromer for the management of hyperkalaemia in patients receiving renin-angiotensin-aldosterone system inhibitors for heart failure: design and rationale of the DIAMOND trial. Eur J Heart Fail. 2022;24(1):230\u20138.","journal-title":"Eur J Heart Fail"},{"key":"581_CR32","unstructured":"DM P, AE A, S D, S P, KR A, NJ W. NICE DSU Technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016 [cited 2023 02\/11\/2023]; https:\/\/www.sheffield.ac.uk\/nice-dsu"},{"key":"581_CR33","unstructured":"Association UR. UK Renal Registry 23rd Annual Report 2021. 2021."},{"issue":"13","key":"581_CR34","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1056\/NEJMoa041031","volume":"351","author":"AS Go","year":"2004","unstructured":"Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296\u2013305.","journal-title":"N Engl J Med"},{"issue":"11","key":"581_CR35","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1161\/CIRCULATIONAHA.105.584102","volume":"113","author":"WC Levy","year":"2006","unstructured":"Levy WC, Mozaffarian D, Linker DT, Sutradhar SC, Anker SD, Cropp AB, et al. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation. 2006;113(11):1424\u201333.","journal-title":"Circulation"},{"issue":"1","key":"581_CR36","doi-asserted-by":"publisher","first-page":"90","DOI":"10.2215\/CJN.01730215","volume":"11","author":"J Luo","year":"2016","unstructured":"Luo J, Brunelli SM, Jensen DE, Yang A. Association between serum potassium and outcomes in patients with reduced kidney function. Clin J Am Soc Nephrol. 2016;11(1):90\u2013100.","journal-title":"Clin J Am Soc Nephrol"},{"key":"581_CR37","unstructured":"Transport NBa. Annual report on kidney transplantation. 2019."},{"issue":"4","key":"581_CR38","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s41669-017-0062-z","volume":"2","author":"C Jommi","year":"2018","unstructured":"Jommi C, Armeni P, Battista M, di Procolo P, Conte G, Ronco C, et al. The cost of patients with chronic kidney failure before dialysis: results from the IRIDE observational study. Pharmacoecon Open. 2018;2(4):459\u201367.","journal-title":"Pharmacoecon Open."},{"issue":"1","key":"581_CR39","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s12882-020-01716-w","volume":"21","author":"E Riccio","year":"2020","unstructured":"Riccio E, Sabbatini M, Capuano I, Pellegrino AM, Petruzzelli LA, Pisani A. Oral Sucrosomial\u00ae iron versus intravenous iron for recovering iron deficiency anaemia in ND-CKD patients: a cost- minimization analysis. BMC Nephrol. 2020;21(1):57.","journal-title":"BMC Nephrol"},{"issue":"2","key":"581_CR40","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1007\/s40620-016-0291-8","volume":"30","author":"A Roggeri","year":"2017","unstructured":"Roggeri A, Roggeri DP, Zocchetti C, Bersani M, Conte F. Healthcare costs of the progression of chronic kidney disease and different dialysis techniques estimated through administrative database analysis. J Nephrol. 2017;30(2):263\u20139.","journal-title":"J Nephrol"},{"issue":"10","key":"581_CR41","doi-asserted-by":"publisher","DOI":"10.1111\/ctr.13728","volume":"33","author":"DP Roggeri","year":"2019","unstructured":"Roggeri DP, Roggeri A, Zocchetti C, Cozzolino M, Rossi C, Conte F. Real-world data on healthcare resource consumption and costs before and after kidney transplantation. Clin Transpl. 2019;33(10): e13728.","journal-title":"Clin Transpl"},{"issue":"4","key":"581_CR42","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1111\/jvh.12639","volume":"24","author":"E Elbasha","year":"2017","unstructured":"Elbasha E, Greaves W, Roth D, Nwankwo C. Cost-effectiveness of elbasvir\/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States. J Viral Hepat. 2017;24(4):268\u201379.","journal-title":"J Viral Hepat"},{"issue":"1","key":"581_CR43","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s12882-019-1250-0","volume":"20","author":"L Horne","year":"2019","unstructured":"Horne L, Ashfaq A, MacLachlan S, Sinsakul M, Qin L, LoCasale R, et al. Epidemiology and health outcomes associated with hyperkalemia in a primary care setting in England. BMC Nephrol. 2019;20(1):85.","journal-title":"BMC Nephrol"},{"issue":"1","key":"581_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1093\/eurheartj\/ehl382","volume":"28","author":"G Yao","year":"2007","unstructured":"Yao G, Freemantle N, Calvert MJ, Bryan S, Daubert JC, Cleland JG. The long-term cost-effectiveness of cardiac resynchronization therapy with or without an implantable cardioverter-defibrillator. Eur Heart J. 2007;28(1):42\u201351.","journal-title":"Eur Heart J"},{"key":"581_CR45","unstructured":"Sodium zirconium cyclosilicate for treating hyperkalaemia, technology appraisal guidance [TA599]. National Institiute for Health and Care Excellence; 2022."},{"key":"581_CR46","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, N W. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submissions to NICE. 2016."},{"issue":"10","key":"581_CR47","doi-asserted-by":"publisher","first-page":"935","DOI":"10.2165\/11538370-000000000-00000","volume":"28","author":"JE Signorovitch","year":"2010","unstructured":"Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Kantor E, Bao Y, et al. Comparative effectiveness without head-to-head trials: a method for matching-adjusted indirect comparisons applied to psoriasis treatment with adalimumab or etanercept. Pharmacoeconomics. 2010;28(10):935\u201345.","journal-title":"Pharmacoeconomics"},{"issue":"1","key":"581_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40273-022-01215-w","volume":"41","author":"P Russo","year":"2023","unstructured":"Russo P, Zanuzzi M, Carletto A, Sammarco A, Romano F, Manca A. Role of economic evaluations on pricing of medicines reimbursed by the Italian National Health Service. Pharmacoeconomics. 2023;41(1):107\u201317.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"581_CR49","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0264123","volume":"17","author":"PA Cortesi","year":"2022","unstructured":"Cortesi PA, Antonazzo IC, Gasperini C, Nica M, Ritrovato D, Mantovani LG. Cost-effectiveness and budget impact analysis of siponimod in the treatment of secondary progressive multiple sclerosis in Italy. PLoS ONE. 2022;17(3): e0264123.","journal-title":"PLoS ONE"},{"key":"581_CR50","doi-asserted-by":"crossref","unstructured":"De Benedetto I, Shbaklo N, Vicentini C, Zotti CM, De Rosa FG, Corcione S. Cost-effectiveness of short course of ceftazidime\/avibactam for K. pneumoniae-KPC bloodstream infections in Italy. Microorganisms. 2023;11(5).","DOI":"10.3390\/microorganisms11051102"},{"issue":"5","key":"581_CR51","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1007\/s40261-021-01023-8","volume":"41","author":"P Ferrara","year":"2021","unstructured":"Ferrara P, Cortesi PA, Di Laura D, Maggioni AP, Mantovani LG. Cost-effectiveness analysis of rivaroxaban plus aspirin compared with aspirin alone in patients with coronary and peripheral artery diseases in Italy. Clin Drug Investig. 2021;41(5):459\u201368.","journal-title":"Clin Drug Investig"},{"issue":"9","key":"581_CR52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s40261-024-01386-8","volume":"44","author":"G Ghetti","year":"2024","unstructured":"Ghetti G, Mennini FS, Marcellusi A, Bischof M, Pistillo GM, Pane M. Cost-effectiveness analysis of newborn screening for spinal muscular atrophy in Italy. Clin Drug Investig. 2024;44(9):687\u2013701.","journal-title":"Clin Drug Investig"},{"issue":"13","key":"581_CR53","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.2217\/cer-2019-0074","volume":"8","author":"C Rognoni","year":"2019","unstructured":"Rognoni C, Gerzeli S. Ferric carboxymaltose for patients with heart failure and iron deficiency in Italy: cost-effectiveness and budget impact. J Comp Eff Res. 2019;8(13):1099\u2013110.","journal-title":"J Comp Eff Res."},{"key":"581_CR54","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez-Juanatey JR, Gonz\u00e1lez-Franco \u00c1, de Sequera P, Valls M, Ramirez de Arellano A, Pomares E, et al. A cost-effectiveness analysis of patiromer for the treatment of hyperkalemia in chronic kidney disease patients with and without heart failure in Spain. J Med Econ. 2022;25(1):640\u20139.","DOI":"10.1080\/13696998.2022.2074193"},{"key":"581_CR55","doi-asserted-by":"publisher","first-page":"S456","DOI":"10.1016\/j.jval.2018.09.2690","volume":"21","author":"E Walter","year":"2018","unstructured":"Walter E, Eichhober G, Voit M. PSY115-A cost-effectivenss analysis of RAASi-enabling patiromer for the treatment of hyperkalemia in Austria. Val Health. 2018;21:S456.","journal-title":"Val Health"},{"key":"581_CR56","unstructured":"Institute of Medicine Committee on Strategies for Small-Number-Participant Clinical Research T. In: Evans CH, Jr., Ildstad ST, editors. Small clinical trials: issues and challenges. Washington (DC): National Academies Press (US) Copyright 2001 by the National Academy of Sciences. All rights reserved.; 2001."},{"issue":"3","key":"581_CR57","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1056\/NEJMoa1410853","volume":"372","author":"MR Weir","year":"2015","unstructured":"Weir MR, Bakris GL, Bushinsky DA, Mayo MR, Garza D, Stasiv Y, et al. Patiromer in patients with kidney disease and hyperkalemia receiving RAAS inhibitors. N Engl J Med. 2015;372(3):211\u201321.","journal-title":"N Engl J Med"},{"issue":"12","key":"581_CR58","doi-asserted-by":"publisher","first-page":"499","DOI":"10.3390\/jcm7120499","volume":"7","author":"M Provenzano","year":"2018","unstructured":"Provenzano M, Minutolo R, Chiodini P, Bellizzi V, Nappi F, Russo D, et al. Competing-risk analysis of death and end stage kidney disease by hyperkalaemia status in non-dialysis chronic kidney disease patients receiving stable nephrology care. J Clin Med. 2018;7(12):499.","journal-title":"J Clin Med"},{"key":"581_CR59","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s40620-019-00617-y","volume":"32","author":"S Bianchi","year":"2019","unstructured":"Bianchi S, Aucella F, De Nicola L, Genovesi S, Paoletti E, Regolisti G. Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. J Nephrol. 2019;32:499\u2013516.","journal-title":"J Nephrol"},{"issue":"7","key":"581_CR60","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1056\/NEJMoa1000552","volume":"363","author":"BA Cooper","year":"2010","unstructured":"Cooper BA, Branley P, Bulfone L, Collins JF, Craig JC, Fraenkel MB, et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med. 2010;363(7):609\u201319.","journal-title":"N Engl J Med"},{"key":"581_CR61","unstructured":"Association UR. UK Renal Registry 8th Annual Report. 2004."},{"issue":"8","key":"581_CR62","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1097\/01.TP.0000438026.03958.7b","volume":"97","author":"A Karim","year":"2014","unstructured":"Karim A, Farrugia D, Cheshire J, Mahboob S, Begaj I, Ray D, et al. Recipient age and risk for mortality after kidney transplantation in England. Transplantation. 2014;97(8):832\u20138.","journal-title":"Transplantation"},{"issue":"5","key":"581_CR63","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1053\/j.ajkd.2015.10.011","volume":"67","author":"X Xie","year":"2016","unstructured":"Xie X, Liu Y, Perkovic V, Li X, Ninomiya T, Hou W, et al. Renin-angiotensin system inhibitors and kidney and cardiovascular outcomes in patients with CKD: a Bayesian network meta-analysis of randomized clinical trials. Am J Kidney Dis. 2016;67(5):728\u201341.","journal-title":"Am J Kidney Dis"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-025-00581-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-025-00581-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T10:02:57Z","timestamp":1751277777000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-025-00581-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,12]]},"references-count":63,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["581"],"URL":"https:\/\/doi.org\/10.1007\/s41669-025-00581-3","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,12]]},"assertion":[{"value":"13 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work was funded by CSL Vifor, which provided support for the model development and analysis and medical writing for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"A.R.d.A. conceptualised and designed the study. E.S. was responsible for data analysis. All authors contributed to interpretation of the results, preparation and review of the manuscript, and approval of the final manuscript for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributors"}},{"value":"A.R.d.A. was an employee of CSL Vifor at the time of original drafts. E.S. and M.H. are employees of Health Economics and Outcomes Research Ltd. Health Economics and Outcomes Research Ltd. received fees from CSL Vifor in relation to this study. E.P. reports consultancy fees from CSL Vifor, AstratZeneca, Astellas and Novartis. M.S. reports consultancy fees from CSL Vifor, Novartis, Merck, Bayer, Abbott, Boehringer Ingelheim, AstraZeneca, Bioventrix, Servier, Novo Nordisk, Cardurion and AnaCardio.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"All data and material relevant to the analysis are presented in the publication or its supplementary material, with the exception of the model itself.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The model used in this study was provided to the journal\u2019s peer reviewers for their reference when reviewing the manuscript, but the model remains the intellectual property of CSL Vifor.\u00a0The authors will respond to all enquiries regarding the details of the analysis upon reasonable request should these not have been answered by the information provided in the \u201cMethods\u201d section.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}}]}}